

Seamless monitoring of (nano)particles for optimized quality control of continuous production processes.


Sensor platform.

Continuous 24/7.

In real-time with single-particle accuracy.



Where we come from ...



BRAVE[®]

A N A L Y T I C S



BASIC RESEARCH

VLPs, liposomes,
proteins, EVs



PHARMA & BIOTECH

Emulsions, vaccines,
anesthetics, infusions



BEAUTY & COSMETICS

Skin lotions, sun
creams



COATINGS

Surface coatings,
surface pigments &
lacquers



ENVIRONMENT

Nanoplastics,
wastewater analysis



MEDICINE

Ceramics & surfaces
in dentistry

Nanoparticle characterization

(range 5 μm - 100 nm)

CURRENT SOLUTIONS



SNAPSHOTS

NO representative results
NO modification possibilities



DELAYS

Cumbersome workflows & complex quality control



HUMAN ERROR

MANUAL processes for cleaning & sample preparation



DURATION

8 HOURS for a TOTAL measurement series of ONE batch



Nanoparticle characterization

(range 5 μm - 100 nm)

THE BRAVE WAY



DEEP INSIGHTS

representative results
complying with current
regulations



ACCURACY

continuous measurements
for seamless quality control



RELIEF

Automated cleaning
procedures
(within 15 seconds)



SPEED

measurement
results in seconds
(time resolved)





SAVES TIME,
WASTE &
RESOURCES


Challenging the state of the art



OF2i® actively induced forces of biophotonics and μ -fluidics to break the barrier of Brownian Motion




Thousands of particles are continuously set in motion as they are pumped through the measuring cell. Using a vortex laser beam, the particles are (de)accelerated by optical forces in spiral paths to prevent collision, while an ultramicroscope camera records the change in velocity of each particle, thereby allowing the size of the nanoparticles to be inferred. How? The recorded motion patterns are evaluated using a theoretical model that is parameter-free, making OF2i a calibration-free system. The model is based on Maxwell's equations as well as generalized Mie theory.



Based on Ashkin et al.
PHYSICS NOBEL PRIZE
2018

Peer-reviewed
technology paper;
PhysRevA Simic et al.




Ready for scale-up

LAB device with modules for more individual insight
BRAVE B-Curious


continuous manufacturing
ready-to-go product

PAT sensor which revolutionizes your production
BRAVE B-Continuous




BRAVE B-Continuous application & extensions

CONTINUOUS PRODUCTION




Automatic sample preparation unit


Online measurement



Counting method with single-particle accuracy requires dilution for highly concentrated samples



BRAVE B-Prepared



Definition: particle count vs. object count




1 OF2i detected particles
Number-based particle size, PSD and concentration
Sizing range: 100 nm - 3000 nm*
Exempl. value: $3,4 \times 10^{13}$ particles/ml
(114 nm - 2750 nm)

2 OF2i detected objects
Total of all objects which were detected by OF2i BUT where TOO SMALL to determine their exact size
Exempl. value: $7,6 \times 10^{18}$ objects/ml


3 Full colloidal system
Objects are present but are out of detection range: cannot be detected with OF2i yet.
=> NOT INCLUDED in detected objects value

OF2i sizing range*




*) sample dependent

OF2i Report: measurement validity



- for 95.0 % of the particles size, PSD and concentration could be measured.
- 5.0 % of the particles were below smallest measurable size (e.g. 100 nm) and could be detected but not sized.
- 0.0 % of the scanned particles were above maximum measurable size (e.g. 3000 nm).




OF2i features in a nutshell

 <p>100 nm* to 5 µm DETECTION RANGE (*sample-dependent)</p>	 <p>REDUCES REJECTS through continuous monitoring</p>	 <p>NO WAITING for lab test results.</p>
 <p>SEAMLESS MEASUREMENTS proven throughput up to 2500 particles/minute.</p>	 <p>RELIABLE & REPRESENTATIVE measurement results</p>	 <p>PROCESS OPTIMIZATION through real-time data.</p>
 <p>TIME RESOLVED RESULTS for understanding kinetic processes</p>	 <p>BASIS for Real-time Release Testing (RTRT)</p>	 <p>MINIMIZES HUMAN ERROR and delays</p>
 <p>ULTRA-LOW PARTICLE CONCENTRATIONS at high THROUGHPUT</p>	 <p>READY TO SCALE-UP from lab to PAT</p>	 <p>Enables PREDICTIVE MAINTENANCE</p>




OF2i® Continuous monitoring: High-pressure homogenization for more efficient quality control



© BRAVE Analytics & Marko Šimić: OF2i® time resolved online characterization as number based size distributions

Monitoring of production processes:

- Object size range: 180 -3000 nm
- Detected substances: biological agents in emulsion
- Measuring mode: online
- Timestep @min 17: detected change homogenization process





Biomolecular research: Understanding Alzheimer's Disease




Prof. Tobias Madl


"The OF2i method closes a huge gap and enables in-depth and seamless observation of the proteins as they change over time, in this case time-resolved information over seconds to hours."



© BRAVE Analytics & Marko Šimić: Time-resolved PSD: Particle formation processes during liquid-liquid phase separation (LLPS) with low (left) and high (right) RNA concentrations over 30 minutes.



Reliable, statistically relevant results for up- and downstream processes for viruses and VLP polydisperse colloid systems




Monitoring of efficiency of downstreaming operations

- Object size range: 50 - 1000 nm
- Detected substances: biologic virus cultures
- Measuring mode: offline

© BRAVE Analytics & ACIB: OF2i reveals additional larger particle fractions, enabling better process understanding.



	NTA	OF2i®
Total measurement time	approx. 45 minutes	approx. 8 minutes ✓
Particle throughput	100/ minute	approx. 360/ minute ✓
Cleaning time after every measurement	approx. 5-8 minutes	approx. 30 seconds ✓

Online monitoring of the leaching of micro- and nanoplastics into water at ultra-low concentrations



Understanding of impact of cleaning cycles:

- 7 cycles performed with 20nm filtrated ultra-pure H₂O
- Object size range: 50-3000 nm (estimated)
- Detected substances: SiO₂, polystyrene, PP, PFAS
- Measuring mode: online




Verification of low-budget screen-printed sensors detecting nano pollutants in surface water



Nanopollutants (from tires) in water suspension

Sample filtered with 0.22 μm filter


PARTICLE SIZE DISTRIBUTION - COUNT BASED



Mean concentration ~ 8E5 objects
D90 - 321.2nm (90% of the population is smaller than 321 nm)

Sample filtered with 0.45 μm filter

PARTICLE SIZE DISTRIBUTION - COUNT BASED



Mean concentration ~ E6 objects
D90 - 406.7nm (90 % of the population is smaller than 406.7 nm)

Measuring nanoplastic concentration and size changes over time at ultra-low concentrations

- Object size range: 180 -3000 nm
- Filtration: 0.22 μm filter compared with 0.22 μm filter
- Detected substances: car tire abrasion in water
- Measuring mode: online
- Timestep 10: fault detection within homogenization process

BRAVE market segments

Exosome diagnostics and therapeutics

VLPs and Viruses

Drug delivery

mRNA therapeutics

Ceramics & surfaces in dentistry

Emulsions and infusions

(nano) Particles in Life Science

Nanobiotechnology

\$ 104.8 BN in 2022
\$ 160.3 BN by 2030

CAGR
5.5 %

Nano medicine

\$ 159.53 BN in 2021
\$ 427.18 BN by 2030

CAGR
11.7 %

Food
Coatings
Beauty & Cosmetics

Environmental
Analysis

\$ 295 BN in 2022
\$ 572.2 BN by 2032

CAGR
6.9 %

BRAVE B-Continuous
Deep insights into your production

Process Analytical Technology
(pharmaceutical industry)

\$ 2.07 BN in 2021
\$ 4.91 BN by 2030

CAGR
10.2 %

High-throughput screening

\$ 18.93 BN in 2021
\$ 36.84 BN by 2030

CAGR
7.82 %

BRAVE B-Curious

The solution for R&D and quality control

Global particle size analyzer market

\$ 395.37 MN in 2022
\$ 695.45 MN in 2032

CAGR
14.4 %

Wet particle size analyzer

\$ 125.33 MN in 2022

CAGR
8.17 %

Market
share
35 %



Pharmaceutical
manufacturing

\$ 425.9 BN in 2021
\$ 1,599.9 BN by 2030

CAGR
15.9 %



BRAVE COLLABORATIONS

USA:

Manufacturing
Process control

GSK

PARIS
LODRON
UNIVERSITÄT
SALZBURG

FH
CAMPUS
WIEN
UNIVERSITY OF APPLIED SCIENCES

KLAR₂

novo nordisk®

AVL

lignovations

Research: Up-/ down streaming
VLP, Viruses (100-800 nm)

LLPS, drug targeting

4
DEVICES
OUT

MONTAN
UNIVERSITÄT
LEOBEN

Manufacturing plants

Water analysis

Med Uni
Graz

BOKU
acib

Research: Up-/ down streaming
VLP, Viruses (100-800 nm)

Water analysis

12
PAID SCIENTIFIC
COLABORATIONS

JOANNEUM
RESEARCH

Manufacturing plants

Research:
LLPS, drug targeting

ViraTherapeutics
Boehringer
Ingelheim

UNI
GRAZ

Research: ICP-MS

Research: Up-/ down streaming
VLP, Viruses (100-800 nm)

FRESENIUS
KABI

Drug manufacturing

University of Ljubljana

Research:
Up-/ down streaming

SARTORIUS
BIA
separation

Down streaming

4
PUBLICATIONS
OUT



FLUIDINOVA
NANOPAT

UNIVERSITÀ
DEGLI STUDI
DI PADOVA

Research:
Up-/ down streaming

creative nano
NANOPAT

A BRAVE future with OF2i-RAMAN coupling



As an addition to the OF2i® technology, which uses elastically scattered radiation, the correlative OF2i®-Raman method employs inelastically scattered radiation for chemical analysis. This approach detects particles smaller than those typically analyzed by regular Raman microscopy (< 500 nm). (publication: Neuper et al.)



WINNER 2023



OF2i-Raman for size, size distribution and chemical analysis of nanoparticles in liquids




Figure 4: OF2i[®]-Raman measurement of 5 μm PS (polystyrene) spheres. **(a)** The image shows a stably trapped single particle at position 1 (P1) and agglomerations at positions 2 and 3 (P2 and P3). Between the inserted squares, the Raman spectra are obtained. **(b)** Spectra of a single 5 μm PS sphere (P1), particle agglomerations (P2 and P3), and a reference spectrum of bulk polystyrene measured with a regular Raman microscope.

Neuper et al.

Volume 415 · Number 21 · September 2023

ANALYTICAL & BIOANALYTICAL CHEMISTRY

GDCh SEQA RSEQ ASAC


Recent Trends in (Bio)Analytical Chemistry

Guest Editors Antje J. Baeumner · Günter Gauglitz

The diagram illustrates the OF2i-Raman setup. A cylindrical tube contains particles (green dots) moving from left to right. A laser beam (green arrows) propagates from right to left. Scattered light is collected and directed to a detector. The Raman spectrum is shown as a series of peaks. Forward and side images are also shown.

Springer

OF2i vs. SingleParticleLightScattering for size, size distribution and chemical analysis of nanoparticles in liquids





In house analysis of penta standards

- Trajectory vs. intensity of NIST traceable standards
- Intensity histogram illustrating particle size, size distribution and occurrence
- Number of detected objects: 14831
- Scattering of particles changes depending on their morphology => e.g. solid vs. core-shell particles

OF2i coupled with Raman Spectroscopy and Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

TiO₂ particles were trapped and analyzed via OF2i-Raman. The experimental Raman spectra (b, e) were compared against those of anatase (c, f) as common TiO₂ phases enabling a clear identification of the former.



Optofluidic Force Induction meets Raman Spectroscopy and Inductively Coupled Plasma - Mass Spectrometry: A new hyphenated technique for comprehensive and complementary characterization of single particles. Christian Neuper, Marko Simic, Thomas E. Lockwood, Raquel Gonzalez de Vega, Ulrich Hohenester, Harald Fitzek, Lukas Schlatt, Christian Hill, David Classes. 2023.

OF2i coupled with Raman Spectroscopy and Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

TiO₂ particles were trapped and analyzed via OF2i-Raman. The experimental Raman spectra (b, e) were compared against those of anatase (c, f) as common TiO₂ phases enabling a clear identification of the former.





Figure 1. Schematic overview of techniques combined in the framework of this study to improve the characterisation of individual particles.

Optofluidic Force Induction meets Raman Spectroscopy and Inductively Coupled Plasma - Mass Spectrometry: A new hyphenated technique for comprehensive and complementary characterization of single particles. Christian Neuper, Marko Simic, Thomas E. Lockwood, Raquel Gonzalez de Vega, Ulrich Hohenester, Harald Fitzek, Lukas Schlatt, Christian Hill, David Classes. 2023.

BRAVE Intellectual Property

STRATEGY

CONTINUOUS PATENT & COMPETITOR RESEARCH
NETWORK & COMMUNITY BUILDING
while keeping
MATHEMATICAL & PHYSICAL MODELLING CONFIDENTIAL

TRADEMARKS

BRAVE[®]
ANALYTICS

OF2i[®]

PATENTS

PATENT ISSUED:
EP 3422364 B1 (HILL, C.)



OPTICAL PARALLELIZATION
FOR INDUSTRIAL THROUGHPUT
(UK, FR, IT, DE, ES, AT, CZ, NL, JPN, USA, CAN, AUS)

PATENT FILED:
A 50549/2022
CALIBRATION PROCEDURE



PATENT FILED:
A 50829/2023
• OF2i RAMAN
SPECTROSCOPY



IP LICENCE

SIGNED AGREEMENT:

- exclusive exploitation
- IP take-over option
- 4 % IP revenue - EUR 300k cap



... an experienced BRAVE TEAM

40 years
lab & application
experience

30 years
programming
experience

45 years
marketing & sales
experience



- MARKO ŠIMIĆ
Physics & Modelling
- MAGDALENA SCHNEIDHOFER
Business Development & Events
- THOMAS GRUBER
Testing & Mechatronics
- DORIS AUER
Lab & Application
- CHRISTIAN NEUPER
Physics & Optical Engineering
- NIKOLA ŠIMIĆ
Physics & Algorithms
- GERHARD PROSSLINER
Founder | COO | CFO
- RAPHAEL HAUER
Physics & Modeling
- MICHAEL SCHNUR
Fluidics, Mechanics & QM
- MAGDALINE OKUMU-HARTWIG
Team Assistant
- VITAN STRASSER
Product & Sales
- MICHAEL LONGHINO
Software & IT
- SARAH KNIGHTS
Marketing & Communications
- CHRISTIAN HILL
Founder | CEO | CTO
- ALEXANDER LELJAK
Design & Engineering

BRAVE MINDS



Dr. Christian Hill

Founder | CEO | CTO

christian.hill@braveanalytics.eu

+43 (0) 676 842 032-320

- PhD in physical chemistry @ Medical University Graz
- Inventor of OF2i
- Extensive experience in particle technologies, basic research, and analytics
- Researcher/ project manager @ Medical University Graz (2013 – current)
- Tech. project manager @ Anton Paar (2002-2010)



Ing. Gerhard Prossliner

Founder | CFO | COO

gerhard.prossliner@braveanalytics.eu

+43 (0) 676 842 032-324

- Master in Biomedical Engineering @ Technical University Graz
- Experienced prototype development of med-tech devices and industrial smart camera systems and laser applications
- Project Leader for Health tech projects @ Joysys GmbH (2014 – 2016)
- Prototyping, manufacturing, testing of med-tech devices @ CNSystems Medizintechnik (2007 – 2013)

BRAVE SUPPORT



Federal Ministry
Republic of Austria
Education, Science
and Research



Federal Ministry
Republic of Austria
Digital and
Economic Affairs



As a partner in the NanoPAT project, BRAVE Analytics has received funding from the European Union's HORIZON 2020 research and innovation programme under grant agreement n°862583.

